Effects of combination therapy of liraglutide and metformin on blood lipid,CRP and cardiac function in patients with coronary artery disease and diabetes
ZHAO Jionghui
LI Junhong
LI Yingqiao
GENG Jinping
GAO Yanan
Abstract：Objective To investigate the effects of combination therapy of liraglutide and metformin on cardiac function,blood lipid and CRP in patients with coronary artery disease and diabetes.Methods Ninety-six cases of patients with coronary artery disease and diabetes were selected,who were treated in hospital from February 2016 to January 2017,and they were divided into the observation group (48 cases) and control group (48 cases).The patients of control group were treated with metformin hydrochloride tablets (initial dose of 500 mg / time,2 times / d,the maximum dose ≤ 2 000 mg / d).On the basis of control group,the patients of observation group were treated with liraglutide (subcutaneous injection,initial dose of 0.6 mg / time,1 time / d;then the dose gradually increased to 1.8mg to maintain).The patients of two groups were all treated for 3 months.Compare the safety of treatment and changes of the blood glucose,blood lipids,and heart function levels of two groups.Results After the treatment,the FPG,2hPG,HbA1c levels of the observation group were significantly lower than those of the control group,the CPO levels of the observation group were significantly higher than those of the control group (t=5.373,t=9.007,t=4.368,t=1.985,P=0.000,P=0.000,P=0.000,P=0.033);The TC,TG,LDL-C,CRP levels of the observation group were significantly lower than those of the control group,the HDL-C levels of the observation group were significantly higher than those of the control group (t=5.233,t=4.495,t=5.536,t=6.683,t=2.052;P=0.000,P=0.000,P=0.000,P=0.000,P=0.021);The LVEF,E/A levels of the observation group were significantly higher than those of the control group,the LVEDD,LVPWT levels of the observation group were significantly lower than those of the control group (t=5.145,t=4.699,t=4.034,t=5.758;P=0.000,P=0.000,P=0.000,P=0.000);There were anorexia,nausea / vomiting,diarrhea,a transient hypoglycemia and other adverse reactions occurred in both two groups,but there were no statistically significant between the two groups (χ2=0.947,χ2=0.634,χ2=1.355,χ2=0.806;P=0.331,P=0.426,P=0.244,P=0.369).Conclusion With treating patients with coronary heart disease and diabetes,liraglutide combined with metformin can effectively improve the heart function and dyslipidemia,reduce the inflammatory response,it is also safe and reliable,which makes it worthy of application.
Keywords：Coronary artery diseaseDiabetesLiraglutideMetforminHeart functionGlucose lipids
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 989-992,996 )